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arfarin sodium is a highly effective drug for the prevention of thromboembolism in a wide variety of cardiovascular conditions. Marked individual variability in the response of the hemostatic system and the potential for significant interaction with other drugs mandates careful and regular monitoring of patients who receive warfarin. In the past decade, several clinical trials have demonstrated unequivocally the efficacy of warfarin for both the primary and secondary prevention of stroke in patients with atrial fibrillation. [1] [2] [3] [4] [5] [6] [7] [8] In view of the high prevalence of atrial fibrillation in the elderly population (estimated to be 1 to 2% of persons of Ͼ70 years of age), the pool of patients who are potential warfarin candidates has both grown and aged.
Despite the proven efficacy of warfarin in clinical trials, several observational studies have shown that many physicians are reluctant to give anticoagulants to patients with atrial fibrillation because of concerns, perceived or real, that the potential for major bleeding outweighs the risks of stroke prevention. [9] [10] [11] [12] [13] [14] [15] The data generated from clinical trials clearly indicate that the benefits of embolic stroke prevention outweigh the risks of major or fatal bleeding by approximately 20 to 1, 16 yet valid concerns have been raised about the applicability of controlled trials to clinical practice. 17 Such concerns revolve around, among other issues, the belief that patients in clinical trials received tighter anticoagulation control than would normally be obtained and that they constituted a small subgroup of patients characterized by reliability and, potentially, a low bleeding risk. Indeed, review of the atrial fibrillation trials that published information on the percentage of screened patients who entered the trial indicates that all but the AFASAK trial recruited less than 10%. Although there were good reasons for many patients not to be enrolled (such as concomitant conditions that required warfarin therapy), a significant number of the nonenrolled patients were trial candidates, and this low percentage reinforces the notion of the potential difference between patients seen in clinical practice and those in the trials.
Despite evidence that many warfarin-eligible patients do not receive anticoagulation, a review of the studies that have addressed this issue [9] [10] [11] [12] [13] [14] [15] does indicate that acceptability of warfarin therapy for stroke prevention is increasing, with a higher percentage of patients receiving warfarin in late 1990 surveys than in those performed in the earlier part of the decade. Certainly increased awareness of the efficacy of warfarin must have played a role, but this decade has also seen the widespread introduction in the United States of the international normalized ratio (INR) to monitor prothrombin times 18 (thereby reducing a tremendous variability in the degree of anticoagulation that results from the use of thromboplastins with different sensitivity) and a greater reliance on anticoagulation clinics rather than individual practitioner control of warfarin therapy. 19 Both of these innovations have been shown to result in improved anticoagulation control and a decreased incidence of major (but not necessarily minor) bleeding. 20 Any physician or nurse who has been responsible for the control of warfarin therapy recognizes the many vagaries of this drug, including interpatient variability of dose, interaction with many other drugs, and fluctuations in the INR associated with intercurrent illnesses, such as an exacerbation of congestive heart failure. The nonlinear pharmacodynamics of warfarin require cautious dosage adjustment to maintain patients within the narrow range of INR wherein bleeding is minimized and antithrombotic effect is maximized. 21, 22 This demands not only great care on the part of the provider, but also reliance on a drug formulation that is consistently within a very narrow range of bioavailability. In 1980, the unannounced substitution by a hospital pharmacy of amorphous warfarin sodium for crystalline warfarin sodium (Coumadin; Dupont Pharma; Wilmington, DE) in a cost-saving attempt resulted in loss of anticoagulation control in a high proportion of patients monitored in the hospital's anticoagulation clinic. 23 The resultant increase in the number of CHEST editorials VOLUME 113 / NUMBER 2 / FEBRUARY, 1998
CHEST / 113 / 2 / FEBRUARY, 1998 patient visits necessitated by this substitution resulted in an increased cost of patient care and in risk of significant bleeding. Amorphous warfarin was subsequently withdrawn from the US market, and crystalline warfarin sodium, produced by a single manufacturer under the brand name Coumadin, has remained the only formulation of warfarin available until now.
Recently, generic crystalline warfarin sodium has been approved by the US Food and Drug Administration (FDA) as a therapeutically equivalent drug to Coumadin. Therapeutic equivalence requires not only that the drug is a pharmaceutical equivalent (ie, has identical active ingredients with identical strength and quality) but also that criteria for bioequivalence are met. Bioequivalence testing is usually determined in a small number of normal volunteers, and the FDA permits the therapeutically "equivalent" drug to differ from the pioneer drug by a ratio and extent of absorption between Ϫ20 and ϩ25%. 24 This range may be clinically acceptable for such drugs as antibiotics or even antiarrhythmic agents, for which the therapeutic range is wide and only roughly correlates with efficacy, but is of particular concern when such drugs as warfarin with a narrow therapeutic range 7,25-28 are discussed. The potential variation in bioavailability among different brands of warfarin may cause significant problems because minor dose changes in susceptible patients, such as the elderly, can result in clinically significant and potentially life-threatening deviations in the INR.
Will the availability of generic warfarin place patients who already receive warfarin at an increased risk if this formulation is used? The answer depends on several factors. These include the closeness of the bioavailability of the generic to the parent product (it is generally the case that generic products fall closer to the innovative product than the Ϫ20 to ϩ25% rule allows), the awareness of physicians that more than one warfarin product exists, and most important, the regulations that govern substitution of one manufacturer's product for another. (This problem will be compounded as other manufacturers produce generic warfarin, which may differ from the parent compound and from the initial generic drug.) In the absence of extensive, large-scale, comparative bioavailability and pharmacodynamic data in elderly patients with multiple comorbid conditions 29 (a frequent profile in the patient with atrial fibrillation), the cost-benefit ratio of such a switch remains unknown. The potential for inadvertent overdose or underdose of anticoagulation is of concern and may be greatest in those states with mandatory substitution laws or for those patients whose insurer demands such substitution.
The introduction of cheaper generic drugs that are truly bioequivalent is to be welcomed, and data that demonstrate such equivalence deserve wide dissemination. 30 ,31 However, we believe that it is vital that substitution of generic for brand-name warfarin or vice versa should not occur without the practitioner's knowledge and that any such substitution be accompanied by an increased frequency of INR monitoring until stability is achieved. Clinical guidelines for using generic substitutes need to be formulated in order to guarantee patients' safety while maximizing the beneficial effects. Much effort has been invested into proving the utility and safety of warfarin in the prevention of thromboembolic events. An equal effort must now be realized to ensure that generic warfarin does not become a wild card that will set back the gradually improving state of knowledge and practice so carefully built up over the last decade. It will be unfortunate indeed if inadequately informed health-care professionals and their patients permit drug substitutions without the safeguards necessary to provide a smooth transition.
Jeanne 
T
he Joint National Committee (JNC) of the National High Blood Pressure Education Program (NHBPEP) has published recurring documents to guide the clinician in prevention, detection, and management of hypertension. The 50th anniversary of the founding of the National Heart, Lung, and Blood Institute and the 25th anniversary of the founding of the NHBPEP within that institute are being marked this year.
While there have been remarkable reductions in morbidity and mortality attributable to hypertension since 1972 (a 60% reduction in age-adjusted death rates from stroke and 53% reduction in death rates from coronary heart disease) coinciding with increased numbers of people controlling their hypertension, these dramatic improvements have slowed. Recent reports from Minnesota have shown a decrease in the awareness, treatment, and control of hypertension compared to 10 years ago. 1,2 Nationally, the prevalence of heart failure and the incidence of end-stage renal disease, for both of which hypertension is a common antecedent, have increased remarkably. Public health challenges also include preventing the rise of blood pressure with age and improving control rates from the current national level of about 28%, with emphasis on controlling isolated systolic hypertension. These observations underscore the need to enhance professional education to translate the results of recent research into improved public health. The sixth report of the JNC provides the busy primary care clinician with succinct contemporary guidelines for prevention, detection, evaluation, and treatment of hypertension. 3 These guidelines contain tables and figures that summarize the text. As in the past, members of the American College of Chest Physicians will receive a copy of these guidelines by mail. This report also will be available on the World Wide Web (http://www. nhlbi.nih.gov/nhlbi/nhlbi.htm) and by calling (301) 251-1222. Cardiovascular risk assessment tools based on data from epidemiologic studies can also be found
on the Web (www.amhrt.org/risk/catalog/risk_ assessment_guide_ca/page28.html).
On this occasion, the JNC utilized an evidencebased approach to the data as well as consensus. It now includes the absolute, as well as relative, benefits resulting from treatment, because the absolute benefit obtained by treating hypertension depends on the absolute risk in the individual or population. Although randomized clinical trials (RCTs) remain the best source of evidence, they have shortcomings (eg, drop-ins, drop-outs; patients at high risk do not participate in the trials; benefits of treatment accrue over a time longer than the duration of the trial) and, thus, treatment effects were extrapolated.
The accurate measurement of blood pressure is described and information is provided about the value of serial self-measurement (at home and at work) and of ambulatory blood pressure monitoring. The normal value for out-of-office daytime blood pressure is Ͻ135/ Ͻ85 mm Hg. Details are provided about obtaining the necessary medical history, physical examination, and limited number of routine tests (urinalysis; CBC; ECG; fasting glucose, potassium, sodium, creatinine, total cholesterol, and high-density lipoprotein cholesterol levels). Optional tests to be considered, particularly when target organ disease or an identifiable cause of hypertension is suspected, include creatinine clearance, microalbuminuria, echocardiogram, ultrasound examination of arteries, ankle/arm systolic pressure index, and levels of low-density lipoprotein cholesterol, triglycerides, calcium, uric acid, thyroid-stimulating hormone, glycated hemoglobin, renin, and aldosterone.
Very important recommendations include: a new three-stage classification of blood pressure for adults, which combines stages 3 and 4 of the classification first detailed in JNC V (1993); recognizing the importance of high-normal blood pressure in contributing to cardiovascular disease and in progressing to stage 1 hypertension; and increased emphasis on detecting overall cardiovascular risks and target organ diseases that can be easily established (Table 1) . Clinicians should place patients into one of three risk categories (A, B, C) which, along with the stage of hypertension, influences the decision about starting antihypertensive drug therapy (earlier or later than "usual") ( Table 1) . A convenient notation encompasses an individual's stage of hypertension and risk status, eg, stage 1C would indicate an average blood pressure of Ͻ160 mm Hg and/or Ͻ100 mm Hg in a person with target organ damage and/or diabetes, prompting the need for aggressive management of the concomitant disorders and cardiovascular risks, as well as treating the blood pressure to perhaps Ͻ140/90 mm Hg. A detailed plan of action and goals should be developed with the patient.
"The goal of prevention and management of hypertension is to reduce morbidity and mortality by the least intrusive means possible." 3 Goal blood pressure is Ͻ140 mm Hg and Ͻ90 mm Hg, with lower goals recommended in certain comorbid conditions such as diabetes, renal failure, and heart failure. Lifestyle changes may prevent hypertension and may be definitive therapy in some individuals with high normal BP, but are adjunctive therapy for all patients with hypertension. The lifestyle modifications recommended for hypertension prevention and management include: weight reduction (initial goal, 10 lbs), moderation in alcohol intake (Ͻ0.5-1.0 oz absolute alcohol), regular physical activity (30-to 45-min brisk walk most days), moderation in sodium intake (100 mmol/day), and increase in potassium intake (90 mmol/day). Tobacco avoidance and aggressive treatment of diabetes mellitus and lipid disorders are most important for overall cardiovascular risk reduction.
Drug therapy is discussed in detail: once-a-day drugs are advised, combinations are useful, and special consideration is given to many comorbid conditions and drugs that affect therapeutic decisions. Managed care programs have an important role in coordinating approaches to care, using various health-care professionals and appropriate frequency of visits, patient counseling, and controlled formularies while monitoring outcomes (eg, blood pressure levels, adherence to therapy, morbidity and mortality, resource utilization). Hypertension experts can provide guidance and counseling, particularly for patients with secondary hypertension, resistance to treatment, and complex comorbid conditions.
When the decision has been made to start drug therapy for uncomplicated primary hypertension, in the absence of contraindications, diuretics and ␤-blockers should be chosen because numerous RCTs have shown a reduction in morbidity and mortality with these agents. There are additional, compelling indications for these and other antihypertensive drugs in certain conditions based on RCTs results. In patients with diabetes type I with proteinuria, angiotensin-converting enzyme (ACE) I agents are indicated; in heart failure, ACE I and diuretics; in myocardial infarction, ␤-blockers (nonintrinsic sympathomimetic activity) and ACE I (with systolic dysfunction). For the treatment of hypertension in older persons, diuretics are preferred, and in those with isolated systolic hypertension, a long-acting dihydropyridine calcium antagonist can also be considered. In other clinical situations where there are not yet sufficient outcomes data, the choice of therapy should be individualized based on the patient's needs. Specific therapies for persons with left ventricular hypertrophy, coronary artery disease, heart failure, pulmonary disorders, pregnancy, and renal insufficiency are described. The choices of drugs in the management of hypertensive emergencies and urgencies include the newer intravenous vasodilators, nicardipine and fenoldopam.
These national guidelines must be adapted and implemented in local and individual situations. Widespread application of the recommendations contained in the report should improve detection, treatment, control, and prevention of hypertension. Further reductions in stroke and coronary disease can be anticipated, and attenuation in end-stage renal disease and heart failure is expected as the NHBPEP looks toward the next 25 years. 
Ventilatory Impairment in Asthma Perceptions vs Measurements

D
ecisions concerning asthma management rely on assessment of respiratory problem severity, its known or projected course, and on the response of individual patients to their disease and treatment. The merits and the limitations of various methods for grading asthma, also called ROAD (reversible obstructive airways disease) or VOID (variable obstructive intrabronchial disease), have been reviewed extensively, 1-5 but the conclusion that "attempts to develop a multifactorial . . . index . . . have been unsuccessful" 2, p 734 encourages additional efforts in this direction. In this issue of CHEST (see page 272), Teeter and Bleecker report that certain pulmonary function tests, the peak expiratory flow rate (PEF or PEFR), and the FEV 1 , are more reliable than subjective perceptions for guiding the treatment of asthma. They also state that a 17% incidence of a "relatively asymptomatic airway obstruction" (if "obstruction" means simply a PEF below established norms) is of questionable significance and that "the long-term outcome of untreated or undertreated asthmatics (italics mine) is not known." The need to examine bronchodilator-induced reversibility for those with "asymptomatic obstruction" is not considered sufficiently in this report.
Both acute and chronic asthma are conventionally graded semiquantitatively as "mild, moderate, or severe." 3(p4) Numeric scales have been devised primarily for clinical research, while it is still recognized that "there is no universally accepted and validated measure of asthma severity." 6 Even the elementary question of the mathematical, possibly exponential or logarithmic, relationship between symptom scores and pulmonary function tests, in particular the plethysmographic computations of airways resistance and conductance, 5, 7 has not been examined adequately.
The realization that clinical indexes do not reflect precisely the degree of ventilatory impairment in asthma 7 has led to a search for a convenient and economic way to monitor airflow variability. [2] [3] [4] [5] Despite the limitations of the original Wright peak flowmeter (Ferraris Medical; Holland, NY) (in use for nearly 30 years) and of several subsequent similar devices, including the newly developed computerized version, 8 which are markedly effort-dependent and detect only abnormalities in larger airways caliber, 4,5 they are widely employed. The current authoritative "Consensus Report" and the "Guidelines" for asthma treatment recommend testing PEF in the medical office, the emergency room (dismissing the problem that during an acute attack patients may not be able to blow), and at home. 3, 4 At work PEF may help detect or raise the suspicion of occupational asthma. 9 But there have also been some negative or critical communications. A survey in Scotland determined that "prescribing peak flow meters . . . is unlikely to improve mortality and morbidity." 10 Supporting this conclusion is the statement that PEF measurements are "not suitable" for the initial diagnosis of asthma, and that monitoring PEF is "not based on any scientific evidence." 11 From Australia it was reported 12 that forced mid-expiratory flow (FEF 25-75 ), tested twice weekly, reflected the course of asthma accurately, supplemented by PEF selfmeasurements twice daily. In fact, "if measurements of flow rates at low lung volumes (FEF 50 , FEF 25-75 ) are not performed . . . patients with pathophysiologic abnormalities . . . linked to the small airways may be underdiagnosed." 4(p19) Obviously the schedule of testing ideally has to be based on an estimate of the rapidity of changes and for a thorough monitoring "the frequency of measurements must equal or exceed the anticipated variability cycle." 5 Records of PEF before and after bronchodilator and/or anti-inflammatory therapy, as well as in the course of natural or experimental bronchoconstrictive challenges, are essential 2,9 for appropriate protective and therapeutic action. The frequent self-measurement of PEF serves the additional purpose of patient education, the value of which has been repeatedly emphasized. 2 (p22), 3,4,10(p1093) , 13 Even though several studies have found a lack of a significant correlation between subjective symptoms and pulmonary function measurements, [1] [2] [3] 5, 7 it has been noted 14 that after checking their PEF at its highs and lows several times daily for 10 to 15 days, patients, including young children, learn to predict their PEF scores before they measure them (author's unpublished observations; 1959-1997). Such fairly accurate self-perception of ventilatory impairment is more in reference to "established personal best values" 3(pp 20-21) than predicted "normal" ranges.
Like the personal perception of "disease," instrumental tests of pulmonary function are subject to multiple influences and, certainly, "instructions . . . do not guarantee" maximum performance. 13 Motivation will have to be ascertained and its positive (a desire to excel and to hide malfunction) as well as negative (an attempt to appear "sicker") effect be noted. Mood has not been found to correlate with either symptoms or PEF, although, predictably, increased symptoms were secondarily associated with a "less pleasant mood." 1 Individual responses to sudden PEF changes also vary markedly. Some athletes, professional singers, wind instrument players, and others with high ventilatory requirements may rush for additional treatment if their PEF drops only by 10%, say, from 500 to 450 L/min. Others, leading a relatively sedentary life, may ignore a PEF below 60% predicted, especially if they are reluctant to take medication to the point of "pharmacophobia," or are unwilling to reduce allergenic exposures such as that to a household pet (author's unpublished observations; 1957-1997).
Evidently neither symptom scores nor ventilatory function measurements provide sufficient guidelines about when and how to treat asthma. Treatment of human beings relying only on numbers can be analogous to an appraisal of a great painting based on the milligrams of each pigment it contains. 14 What is needed is patient education, to improve each person's judgment and the capacity for self-care. The current flood of data, with 90,360 documents on the World Wide Web matching the word asthma 15 and a reported "loss of trust" for physicians turning into "acute suspicion," has prompted some journalistic comments about "prescribing just what the patient ordered." 15 If this were to mean total patient autonomy, we know that it could result in serious undertreatment, or overtreatment that might interfere with physiologic regulatory, cybernetic 16 processes and actually amplify asthma. 17 The logical solution, of course, is the establishment of a close rapport and a workable line of communications between pa-tients and the health-care team. Securely supported by the necessary technical and laboratory data, clinicians must continue to listen to their patients' personal perceptions and to make consistent efforts to understand their "subjective," all too human, expectations and needs.
Constantine John Falliers, MD Denver
Director, Allergy and Asthma Clinic, PC; Clinical Professor, Internal Medicine and Pediatrics Departments, University of Colorado School of Medicine.
Prolonged Use of Ventilator Circuits and VentilatorAssociated Pneumonia
A Model for Identifying the Optimal Clinical Practice
I n this issue of CHEST (see page 405), Fink and colleagues describe their experience using various change intervals for ventilator circuit tubing at a tertiary teaching hospital. Using a sequential study design, these authors demonstrated that the incidence of ventilator-associated pneumonia (VAP) was significantly lower with circuit change intervals of either 7 days (3.3 per 1,000 ventilator days) or 30 days (6.3 per 1000 ventilator days) compared to their established practice of changing ventilator circuits every 2 days (11.9 per 1,000 ventilator days) (pϭ0.0004). Additionally, extending the use of ventilator circuits to 30 days resulted in a cost savings of $4,231 for each ventilator in use at their institution.
It is important to note that the design of this study has several important limitations that restrict the general application of the authors' findings. First, a sequential design was used which did not adequately control for ongoing changes in medical practices at the study facility. An important example of this is the switch to heated wire circuits which occurred after the second year of the study. The use of heated wire circuits may have decreased the incidence of VAP by reducing the accumulation of contaminated tubing condensate. Several studies have suggested that the presence of such condensate increases the risk of developing VAP. 1,2 Second, severity of illness and hospital mortality between the study groups was not compared. Therefore, we cannot ascertain the full impact of the intervention on patient outcomes. Third, a clinical diagnosis of VAP was employed which did not rely on quantitative lower airway cultures. This clinical method of establishing the diagnosis of VAP is controversial due to its lack of specificity. 3 However, investigations suggest that the use of clinical criteria are acceptable due to their greater sensitivity and their good correlation with patient outcomes. 4, 5 Despite the limitations noted, this investigation provides additional data confirming the safety and cost-effectiveness of prolonged ventilator circuit usage. To facilitate recommendations regarding specific medical practices, qualities of evidence for grading the available medical literature are published and have already been applied to patients requiring mechanical ventilation. 6, 7 At present, the results of available randomized controlled trials and large before-and-after investigations strongly suggest that extended use of ventilator circuits is a safe practice among acutely ill patients requiring mechanical ventilation. [8] [9] [10] These studies have built upon earlier observational investigations that suggested that less frequent ventilator circuit changes could be safe. 11, 12 In fact, several of these studies have also found that the incidence of VAP is greater among patients undergoing more frequent ventilator circuit changes. 8, 12 These studies support the hypothesis that it is not simply bacterial colonization of the ventilator circuit which predisposes to the development of VAP, but rather the aspiration of contaminated liquid boluses that may be more likely to occur with manipulation of the ventilator circuit. 8 The available published studies should allow the Centers for Disease Control and Prevention (CDC) to change their present recommendations regarding the extended use of ventilator circuits in the ICU setting. The current CDC recommendations provide no maximum length of time that ventilator circuits can be safely left in place during mechanical ventilation. 13 Similarly, the CDC offers no specific recommendations for ventilator circuit changes in chronically ventilated patients. However, a recent report suggested that routine ventilator circuit changes are not required for patients receiving such long-term mechanical ventilation. 14 The most important aspect of the ventilator circuit story may be the stepwise systematic evaluation of this issue over the past 2 decades. This has allowed more specific practice guidelines to be generated regarding the use of ventilator circuits. 6 At our institution we currently change ventilator circuits only when they become visibly soiled (with blood or emesis) or develop air leaks. 8 Current socioeconomic pressures to decrease medical care costs have often resulted in an urgency to change medical practices within medical institutions despite the lack of rigorous outcomes data supporting the safety of such changes. Unfortunately, such a strategy has resulted in unforeseen detrimental effects on patient outcomes, particularly within ICUs. [15] [16] [17] The changing practice of ventilator circuit utilization has avoided such pitfalls, in large part, due to its rigorous investigation.
Making rational changes in medical practices based on the strength of rigorously obtained scientific data is at the heart of the current evidencebased medicine movement. 18 However, when the available scientific evidence regarding the best medical practice is either unconvincing or absent, then this should be seen as an opportunity for designing and performing clinical studies to resolve that issue. The recent experience in identifying the optimal practice for ventilator circuit changes should serve as a paradigm for conducting outcomes research in order to define optimal ICU practices. Additionally, this experience suggests that support of such studies should be viewed as a good investment of clinical research dollars given the resultant establishment of safe and cost-effective medical practices.
Marin H. Kollef 
I
n the past 15 years, more than a dozen studies have described the outcomes of critically ill HIVinfected patients. Most of these studies described outcomes for patients with Pneumocystis carinii pneumonia (PCP) and respiratory failure because, for the 1st decade of the AIDS epidemic, the majority of HIV-positive patients cared for in the ICU had PCP. 1 More recently, with the widespread use of effective prophylaxis, the incidence of PCP has decreased dramatically. 2 Consequently, the spectrum of HIV-related disease in the ICU is changing, and PCP now accounts for only 15 to 25% of HIV-related ICU admissions. 3, 4 The evolution of predicting outcome of ICU care for HIV-related PCP tells a cautionary tale. Before 1986, several small studies showed that only 13 to 18% of patients with PCP and respiratory failure survived to hospital discharge. 1, 5 Between 1988 and 1991, however, multiple studies suggest that hospital survival from PCP and respiratory failure ranged from 40 to 55%. [6] [7] [8] More recently, three studies have suggested that this hospital survival rate has declined to 15 to 25%. [9] [10] [11] The proportion of patients with PCP who died without ICU care changed as a reflection of these published series: patients rarely died without receiving ICU care before the early reports, but forgoing ICU care increased after early reports of poor survival and then decreased again after reports of higher survival. 9, 12 If physicians and patients choose to forgo ICU care for those most likely to die, changes in ICU use will influence the proportion of ICU patients who survive to hospital discharge: the more ICU care is selectively withheld, the better ICU survival will appear. Because the majority of HIV-positive patients who die in the hospital do not receive ICU care, 3 it is likely that variations in ICU use have an important effect on survival after ICU care.
Recently, several articles have described the outcomes of a wider spectrum of disease for patients with HIV infection cared for in the ICU. 4 Lazard and colleagues 4 studied 120 consecutive HIV-positive patients admitted to a medical ICU in Paris between 1990 and 1992. They found ICU survival was associated with the severity of the acute illness prompting ICU admission, whereas long-term survival was associated with functional status and the degree of progression of HIV disease. In this issue of CHEST (see page 421), Casalino and colleagues studied all patients admitted to an infectious disease ICU at a different Paris hospital between 1990 and 1992; the study encompassed 354 patients with a first ICU admission. These authors showed that short-term survival was associated with the nature and severity of the acute illness, whereas long-term survival was associated with factors that predict the severity of underlying HIV disease, such as functional status, number of opportunistic infections, CD4 cell count, and duration of AIDS.
There are several goals for determining the outcomes of intensive care. First, if we can identify patients for whom ICU care is futile, whose chance of meaningful survival is zero or near zero, we can counsel these patients and their families that aggressive care is not indicated. There are only a few instances where this goal has been achieved. 13, 14 Casalino and colleagues, as they point out, are not able to identify a subgroup of HIV-positive patients for whom ICU care is futile. A second goal of determining outcomes of ICU care is to help patients and their families understand the risks and benefits of this care. The article by Casalino and colleagues provides substantial information in this regard. The short-term outcomes of intensive care for persons with HIV infection depend on the nature and severity of the acute illness and are not substantially influenced by the degree of immune suppression from HIV infection. On the other hand, if patients survive the hospital stay, their long-term outcomes depend on the degree of progression of the underlying HIV disease.
An interesting feature of the study by Casalino and colleagues is that it addresses the important issue of patient-centered outcomes. In particular, they examine the functional status of patients after an ICU stay. Assessment of functional status and other patient-assessed outcomes, such as quality of life, is an important and underdeveloped area in ICU outcomes research. The measure of functional status used by Casalino and colleagues, the Karnofsky score, is a rather crude measure and was only assessed on a subset of the survivors. Nonetheless, the authors showed that most of the patients returned to a functional status similar to their baseline before the critical illness. This is important information for patients and their physicians because many patients would not choose ICU care if the outcome was survival with a markedly diminished functional status or quality of life. Future studies should incorporate reliable and valid measures of quality of life and functional status among the other outcomes of ICU care, especially for those patients with chronic or terminal diseases.
We need to learn a lesson from the changing survival after acute respiratory failure due to PCP: things change. Treatment for the underlying HIV infection has undergone dramatic changes in the past 2 years. There are now more than 10 antiretroviral drugs approved in the United States for the treatment of HIV infection, and the clinical improvements recently obtained with combination drug therapy are unprecedented. Persons with HIV infection are having dramatic responses, not just in virologic markers, but in improved functional status, quality of life, and survival. 15 Despite the problems in providing access to these therapies, the Centers for Disease Control and Prevention recently reported a significant decline in the death rate from HIV infection in the United States for the first time since the AIDS epidemic started. 16 These dramatic changes in treatment for HIV infection will almost certainly improve the long-term outcomes of ICU care and may affect the reasons for admission to the ICU, as well as the short-term outcomes. Only continued studies of ICU outcomes for patients with HIV infection will provide physicians and patients the information they need to make decisions about whether and when ICU care is in the best interest of patients.
J. Randall Curtis, MD, MPH* Seattle
Is Less Better?
T he past few years have seen video-assisted thoracic surgery (VATS) gradually becoming the preferred approach for selected surgical procedures. 1 The benefits of VATS over conventional surgery are abundant. Standard thoracotomy is one of the most painful incisions, and the chest is probably the most suitable body cavity for minimally invasive surgery. By virtue of the rigidity of the chest wall, once the lung is collapsed, there is ample room for maneuvering instruments.
VATS is still in evolution. The question is, does VATS, as we currently practice it, represent an end point that only requires minor refinements or is it an intermediate step to an even less invasive approach? We believe that both views may be correct. VATS represents a spectrum with a purely endoscopic approach at one end and a video-assisted approach (with a utility minithoracotomy) at the other end. For the purely endoscopic procedures, there have been attempts to modify further the surgical access and mode of anesthesia. The former resulted in the development of 2-mm "needlescopic" instruments and the latter in therapeutic thoracoscopy under local anesthesia. 2 It is entirely possible that in the future, thoracoscopic sympathectomy and splanchnicectomy could be performed under local anesthesia via an essentially percutaneous route with miniaturized instruments as an outpatient procedure. 3 In this issue of CHEST (see page 528), Noppen and colleagues report the use of thoracoscopic splanchnicolysis in patients with severe pancreatic or postoperative epigastric pain refractory to conservative management. The authors emphasized their own VATS technique of general anesthesia without selective one-lung ventilation, using electrocautery instead of surgical division of nerve fibers, and not using chest drains postoperatively. The relative merits of their technique could only be judged based on the long-term results and morbidity compared with a standard VATS approach (with selective one-lung ventilation and division of nerve fibers). These data, however, are not available. The authors' failure to achieve prolonged pain relief in three of eight patients is difficult to interpret because contralateral interventions were refused by those patients. However, one must be assured that this is not related to inadequate exposure due to the partially ventilated lung or to incomplete cauterization of the nerves. The other question that immediately lends itself to debate is whether these maneuvers made the procedure less invasive. Thoracoscopic splanchnicectomy was first reported by Worsey et al. 4 This and subsequent reports showed that the morbidity is very low and recovery rapid after a standard VATS approach.
Attempts to further minimize the trauma of thoracic surgery should be encouraged. However, these new techniques must obey the principles of advances in surgery, ie, carry added benefits to patients without compromising the results that can be achieved by already available techniques. It is also important not to overlook the potential risks of intrathoracic operations, for one should not erroneously believe that minimally invasive operations will ever equate with minor surgery. 5 The operator must be equipped to handle any intraoperative complications that may arise. These were some of the concerns raised when VATS was first introduced, 6 and they will continue to exist even if the trauma of thoracic surgery can be further minimized. Carefully conducted clinical trials should precede the general acceptance of a new technique or technology, no matter how attractive it may appear initially.
